Gramont Baptiste, Bertoletti Laurent, Roy Michel, Roblin Xavier, Tardy Bernard, Cathébras Pascal
Service de médecine interne, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France.
Service de médecine vasculaire et thérapeutique, CHU de Saint-Étienne, 42055 Saint-Étienne, France.
Therapie. 2020 Nov-Dec;75(6):649-662. doi: 10.1016/j.therap.2020.03.002. Epub 2020 Jun 4.
Proton pump inhibitors (PPIs) have improved the management and prevention of digestive diseases, leading to a heavy prescription of this therapy. In 2015, nearly one quarter of the French population had consumed a PPI and half of them were long-term users. The main objective of this study was to analyze, in patients hospitalized in several medical departments, the adequacy of long-term PPI prescriptions to recommendations.
The Use and management of proton pump inhibitors: an observational study project (UTOPPIA) is a longitudinal observational study conducted at the University Hospital of Saint-Étienne in the departments of hepato-gastroenterology, infectious and tropical diseases, internal medicine, vascular medicine and nephrology. All patients with PPI treatment on their usual outpatient prescription were interviewed.
Over a 3-month period, 334 of hospitalized patients (30.7%) had received a long-term PPI prescription and 181 patients (54.2%) could be included in the study for a total of 274 indications. Ninety-nine patients (54.7%) had a long-term PPI prescription in accordance with the recommendations. The most frequent indication (70 prescriptions) was the prescription of an antiplatelet drug or anticoagulant for subjects at high risk of bleeding in 70 prescriptions. Fifty-three PPI treatments were amended during the hospital stay, including 9 discontinuations. The justification for the change was documented in the patients' chart in only 17% of cases. Individual interviews of patients revealed that 75.1% of them were in favour of discontinuing their PPI treatment.
About one-third of hospitalized patients in medical wards in France have long-term PPI treatment and half of these prescriptions do not comply with good practice recommendations. A majority of patients report being willing to try to stop PPI therapy.
质子泵抑制剂(PPI)改善了消化系统疾病的管理和预防,导致该疗法的处方量很大。2015年,近四分之一的法国人口服用过PPI,其中一半是长期使用者。本研究的主要目的是分析在多个医学科室住院的患者中,长期PPI处方与推荐标准的符合程度。
质子泵抑制剂的使用与管理:一项观察性研究项目(UTOPPIA)是在圣艾蒂安大学医院的肝胃肠病学、感染性和热带病学、内科、血管医学和肾脏病学科室进行的纵向观察性研究。对所有在其常规门诊处方中有PPI治疗的患者进行了访谈。
在3个月的时间里,334名住院患者(30.7%)接受了长期PPI处方,181名患者(54.2%)可纳入研究,共有274个适应证。99名患者(54.7%)的长期PPI处方符合推荐标准。最常见的适应证(70例处方)是为出血高危患者开具抗血小板药物或抗凝剂的处方。53例PPI治疗在住院期间进行了调整,其中9例停药。仅17%的病例在患者病历中记录了变更的理由。对患者的个人访谈显示,75.1%的患者赞成停止PPI治疗。
法国内科病房约三分之一的住院患者接受长期PPI治疗,其中一半的处方不符合良好实践推荐标准。大多数患者表示愿意尝试停止PPI治疗。